Jazz Pharmaceuticals (JAZZ) Projected to Post Quarterly Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ) will likely be issuing its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect the company to announce earnings of $5.87 per share and revenue of $1.1090 billion for the quarter. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS.Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period in the previous year, the firm posted $5.30 earnings per share. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. On average, analysts expect Jazz Pharmaceuticals to post $17 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $137.64 on Monday. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. Jazz Pharmaceuticals has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The stock’s 50-day moving average is $132.19 and its two-hundred day moving average is $118.35. The firm has a market cap of $8.35 billion, a P/E ratio of -20.45, a PEG ratio of 8.49 and a beta of 0.28.

Insider Activity

In other news, Director Bruce C. Cozadd sold 3,500 shares of the company’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $140.00, for a total transaction of $490,000.00. Following the completion of the sale, the director owned 408,826 shares in the company, valued at approximately $57,235,640. This represents a 0.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 11,500 shares of company stock worth $1,525,280. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several large investors have recently made changes to their positions in JAZZ. Geneos Wealth Management Inc. boosted its stake in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Jazz Pharmaceuticals during the 1st quarter valued at approximately $90,000. EverSource Wealth Advisors LLC boosted its stake in Jazz Pharmaceuticals by 53.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 902 shares of the specialty pharmaceutical company’s stock valued at $96,000 after purchasing an additional 313 shares during the period. Strategic Investment Advisors MI bought a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $233,000. Finally, Headlands Technologies LLC bought a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at approximately $331,000. Institutional investors own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on JAZZ. The Goldman Sachs Group upped their target price on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Friday, August 29th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. Royal Bank Of Canada upped their target price on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a research report on Thursday, August 28th. Wells Fargo & Company set a $170.00 target price on Jazz Pharmaceuticals in a research report on Wednesday, October 22nd. Finally, Zacks Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $179.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.